Search | IOVS | ARVO Journals

Showing 1 – 17 of 17

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

Physiology and Pharmacology March 2021

NCX 667, a Novel Nitric Oxide Donor, Lowers Intraocular Pressure in Rabbits, Dogs, and Non-Human Primates and Enhances TGFβ2-Induced Outflow in HTM/HSC Constructs

PDF

Elena Bastia; Carol B. Toris; Stefania Brambilla; Corinna Galli; Nicoletta Almirante; Michael V. W. Bergamini; Emanuela Masini; Silvia Sgambellone; Andrea M. Unser; Feryan Ahmed; Karen Y. Torrejon; Tomas Navratil; Francesco Impagnatiello
TAGS: animal model, dog, domestic, intraocular pressure, ocular hypertension, oryctolagus cuniculus, nitric oxide, primates, donors, cyclic gmp
Invest. Ophthalmol. Vis. Sci.. 2021; 62(3):17. doi: https://doi.org/10.1167/iovs.62.3.17

ARVO Annual Meeting Abstract June 2020

Intraocular pressure (IOP)-lowering effects of NCX 1770, a dual acting new chemical entity with nitric oxide (NO) and phosphodiesterase type-5 (PDE5) inhibitory properties in rabbit and non-human primate models of ocular hypertension and glaucoma

Elena Bastia; Carol Toris; Michael V W Bergamini; Stefania Brambilla; Corinna Galli; Nicoletta Almirante; Francesco Impagnatiello

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):1232. doi:

ARVO Annual Meeting Abstract June 2020

Intraocular pressure (IOP) reduction elicited with NCX 1741, a dual acting nitric oxide (NO) and phosphodiesterase type-5 (PDE5) inhibitor or travoprost in a non-human primate model of ocular hypertension and glaucoma

Francesco Impagnatiello; Tomas Navratil; Carol Toris; Michael V W Bergamini; Stefania Brambilla; Corinna Galli; Nicoletta Almirante; Elena Bastia

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):2786. doi:

ARVO Annual Meeting Abstract July 2019

NCX 1741, a novel NO-donating derivative of the phosphodiesterase-5 inhibitor avanafil, reduces IOP in models of ocular hypertension and glaucoma

Francesco Impagnatiello; Elena Bastia; Carol B Toris; Shan Fan; Stefania Brambilla; Corinna Galli; Nicoletta Almirante; Michael V W Bergamini

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):3770. doi:

ARVO Annual Meeting Abstract July 2019

Nonclinical development of NCX 470, a novel nitric oxide (NO)-donating,IOP lowering prostaglandin analog for glaucoma and ocular hypertension

Elena Bastia; Nicoletta Almirante; Michael V W Bergamini; Tomas Navratil; Marlene Woodruff Modi; Francesco Impagnatiello

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):3806. doi:

ARVO Annual Meeting Abstract July 2019

Concomitant dosing of the NO-donor NCX 667 (1%) and Xalatan® (latanoprost ophthalmic solution 0.005%) results in robust and sustained IOP-lowering in ocular normotensive dogs

Michael V W Bergamini; Tomas Navratil; Francesco Impagnatiello; Elena Bastia

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):3193. doi:

ARVO Annual Meeting Abstract June 2017

Repeated dosing of NCX 667, a new nitric oxide (NO) donor, retains IOP-lowering activity in animal models of glaucoma

Elena Bastia; Francesco Impagnatiello; Ennio Ongini; Janet B Serle; Michael V W Bergamini

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):2106. doi:

ARVO Annual Meeting Abstract September 2016

IOP-lowering effects of NCX 667 in combination with travoprost in ocular normotensive and transient hypertensive rabbits

Elena Bastia; Emanuela Masini; Mariaconcetta Durante; Michael V.W. Bergamini; Ennio Ongini; Francesco Impagnatiello

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):3031. doi:

ARVO Annual Meeting Abstract September 2016

Intraocular pressure-lowering and ocular exposure of NCX 1653, a novel nitric oxide-donating travoprost in models of ocular hypertension and glaucoma

Francesco Impagnatiello; Laura Storoni; Stefania Brambilla; Emanuela Masini; Cecilia Lanzi; Carol B Toris; Michael V.W. Bergamini; Ennio Ongini; Elena Bastia

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):3034. doi:

Glaucoma October 2015

Intraocular Pressure–Lowering Activity of NCX 470, a Novel Nitric Oxide–Donating Bimatoprost in Preclinical Models

PDF

Francesco Impagnatiello; Carol B. Toris; Minerva Batugo; Ganesh Prasanna; Valentina Borghi; Elena Bastia; Ennio Ongini; Achim H. P. Krauss
TAGS: bimatoprost, intraocular pressure, ocular hypertension, nitric oxide, oryctolagus cuniculus, cyclic gmp
Invest. Ophthalmol. Vis. Sci.. 2015; 56(11):6558-6564. doi: https://doi.org/10.1167/iovs.15-17190

ARVO Annual Meeting Abstract June 2015

NCX 667, a novel nitric oxide (NO) donor lowers intraocular pressure (IOP) in ocular normotensive and hypertensive eyes of rabbits and non-human primates

Elena Bastia; Francesco Impagnatiello; Nicoletta Almirante; Cecilia Lanzi; Emanuela Masini; Carol B Toris; Ennio Ongini

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):1999. doi:

ARVO Annual Meeting Abstract June 2015

NCX 470, a nitric oxide (NO)-donating bimatoprost lowers intraocular pressure in rabbits, dogs and non-human primate models of glaucoma

Francesco Impagnatiello; Elena Bastia; Carol B Toris; Achim H Krauss; Ganesh Prasanna; Ennio Ongini

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):5809. doi:

Review August 2014

Nitric Oxide (NO): An Emerging Target for the Treatment of Glaucoma

PDF

Megan E. Cavet; Jason L. Vittitow; Francesco Impagnatiello; Ennio Ongini; Elena Bastia
TAGS: donors, glaucoma, intraocular pressure, nitric oxide
Invest. Ophthalmol. Vis. Sci.. 2014; 55(8):5005-5015. doi: https://doi.org/10.1167/iovs.14-14515

ARVO Annual Meeting Abstract June 2013

The NO donor, isorbide-5-mononitrate alone or combined with timolol, latanoprost or dorzolamide ameliorates intraocular pressure and ocular hemodynamic in an experimental model of glaucoma in rabbits

Francesco Impagnatiello; Barbara Giambene; Francesca Fabrizi; Elena Bastia; Fernando Galassi; Emanuela Masini

Invest. Ophthalmol. Vis. Sci.. 2013; 54(15):4449. doi:

ARVO Annual Meeting Abstract June 2013

Effects of diverse Nitric Oxide donation on ocular hemodynamic and intraocular pressure in normotensive rabbits

Elena Bastia; Francesco Impagnatiello; Daniela Miglietta; Barbara Giambene; Emanuela Masini; Nicoletta Almirante

Invest. Ophthalmol. Vis. Sci.. 2013; 54(15):4450. doi:

ARVO Annual Meeting Abstract June 2013

Intraocular pressure and cGMP aqueous humor levels in spontaneous ocular hypertensive rabbits and following transient IOP changes

ennio ongini; Elena Bastia; Francesco Impagnatiello

Invest. Ophthalmol. Vis. Sci.. 2013; 54(15):426. doi:

ARVO Annual Meeting Abstract April 2011

The Nitric Oxide (no)-donating Triamcinolone Acetonide, NCX 434, Does Not Increase Intraocular Pressure and Reduces Endothelin-1-induced Biochemical and Functional Changes In The Rabbit Eye

Francesco Impagnatiello; Barbara Giambene; Cecilia Lanzi; Alessandro Pini; Teresa Somma; Elena Bastia; Ennio Ongini; Ugo Menchini; Fernando Galassi; Emanuela Masini

Invest. Ophthalmol. Vis. Sci.. 2011; 52(14):6065. doi:

NARROW

Content Type

Journal

Article Type

Topics

Tags

Specify Date Range

NCX 667, a Novel Nitric Oxide Donor, Lowers Intraocular Pressure in Rabbits, Dogs, and Non-Human Primates and Enhances TGFβ2-Induced Outflow in HTM/HSC Constructs

Intraocular pressure (IOP)-lowering effects of NCX 1770, a dual acting new chemical entity with nitric oxide (NO) and phosphodiesterase type-5 (PDE5) inhibitory properties in rabbit and non-human primate models of ocular hypertension and glaucoma

Intraocular pressure (IOP) reduction elicited with NCX 1741, a dual acting nitric oxide (NO) and phosphodiesterase type-5 (PDE5) inhibitor or travoprost in a non-human primate model of ocular hypertension and glaucoma

NCX 1741, a novel NO-donating derivative of the phosphodiesterase-5 inhibitor avanafil, reduces IOP in models of ocular hypertension and glaucoma

Nonclinical development of NCX 470, a novel nitric oxide (NO)-donating,IOP lowering prostaglandin analog for glaucoma and ocular hypertension

Concomitant dosing of the NO-donor NCX 667 (1%) and Xalatan® (latanoprost ophthalmic solution 0.005%) results in robust and sustained IOP-lowering in ocular normotensive dogs

Repeated dosing of NCX 667, a new nitric oxide (NO) donor, retains IOP-lowering activity in animal models of glaucoma

IOP-lowering effects of NCX 667 in combination with travoprost in ocular normotensive and transient hypertensive rabbits

Intraocular pressure-lowering and ocular exposure of NCX 1653, a novel nitric oxide-donating travoprost in models of ocular hypertension and glaucoma

Intraocular Pressure–Lowering Activity of NCX 470, a Novel Nitric Oxide–Donating Bimatoprost in Preclinical Models

NCX 667, a novel nitric oxide (NO) donor lowers intraocular pressure (IOP) in ocular normotensive and hypertensive eyes of rabbits and non-human primates

NCX 470, a nitric oxide (NO)-donating bimatoprost lowers intraocular pressure in rabbits, dogs and non-human primate models of glaucoma

Nitric Oxide (NO): An Emerging Target for the Treatment of Glaucoma

The NO donor, isorbide-5-mononitrate alone or combined with timolol, latanoprost or dorzolamide ameliorates intraocular pressure and ocular hemodynamic in an experimental model of glaucoma in rabbits

Effects of diverse Nitric Oxide donation on ocular hemodynamic and intraocular pressure in normotensive rabbits

Intraocular pressure and cGMP aqueous humor levels in spontaneous ocular hypertensive rabbits and following transient IOP changes

The Nitric Oxide (no)-donating Triamcinolone Acetonide, NCX 434, Does Not Increase Intraocular Pressure and Reduces Endothelin-1-induced Biochemical and Functional Changes In The Rabbit Eye

To View More...

You must be signed into an individual account to use this feature.